# Semaglutide Domain - Domain-Driven Design

## Introduction

The semaglutide domain applies Domain-Driven Design to the clinical management of semaglutide therapy, a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes mellitus and chronic weight management. Semaglutide therapy involves a multifaceted clinical workflow spanning patient eligibility determination, dose titration over weeks to months, ongoing efficacy monitoring, adverse event surveillance, and complex pharmacy operations including specialty dispensing and insurance authorization. The domain must model the dual-indication nature of the medication, where the same pharmacological agent serves distinct clinical purposes with different dosing regimens, eligibility criteria, and outcome measures.

The domain is organized into six bounded contexts that reflect the natural divisions within semaglutide therapy management: patient eligibility and enrollment, dosing and titration, clinical outcomes monitoring, adverse event management, pharmacy and supply operations, and regulatory compliance. Each bounded context maintains its own internal consistency while communicating with other contexts through domain events that enable coordinated clinical workflows, such as triggering enhanced monitoring when dose escalation occurs or initiating pharmacovigilance reporting when adverse events are identified.

## Bounded Contexts

1. **Patient Eligibility and Enrollment Context** - Determines whether a patient is a suitable candidate for semaglutide therapy based on BMI thresholds, existing diagnoses (type 2 diabetes or obesity), comorbidity profiles, contraindication screening, and insurance coverage verification. This context manages the prior authorization workflow and informed consent process that must be completed before treatment initiation.

2. **Dosing and Titration Context** - Manages the dose escalation schedule that gradually increases semaglutide from an initial low dose to the target therapeutic dose over a defined titration period. This context tracks the current dose level, schedules upcoming escalation steps, handles missed dose logic, and records whether the patient is receiving subcutaneous injection (Ozempic/Wegovy) or oral tablet (Rybelsus) formulation.

3. **Clinical Outcomes Monitoring Context** - Tracks the therapeutic efficacy of semaglutide treatment through periodic measurements including body weight, HbA1c levels, blood pressure, lipid panels, and patient-reported outcome questionnaires. Outcomes are benchmarked against clinical trial data from the STEP and SUSTAIN programs to assess individual response adequacy.

4. **Adverse Event Management Context** - Identifies, grades, and manages side effects associated with semaglutide therapy, with particular attention to gastrointestinal events (nausea, vomiting, diarrhea), pancreatitis indicators, thyroid abnormalities, and gallbladder events. Severe adverse events trigger pharmacovigilance reporting workflows to the FDA MedWatch system.

5. **Pharmacy and Supply Context** - Handles prescription processing, specialty pharmacy coordination, cold chain logistics for injectable formulations, inventory management, and patient assistance program enrollment. This context interfaces with pharmacy benefit managers to manage prior authorization renewals and step therapy requirements.

6. **Regulatory and Compliance Context** - Ensures that all prescribing, dispensing, and monitoring activities comply with FDA-approved labeling, documents any off-label use, manages post-market surveillance obligations, and maintains audit trails for regulatory inspection readiness.

## Strategic Design

- The semaglutide domain is classified as a core subdomain where the dosing and titration lifecycle serves as the central organizing concept, with treatment pathways diverging based on the approved indication (type 2 diabetes vs. chronic weight management).
- Context mapping uses a partnership relationship between the Dosing and Titration Context and the Clinical Outcomes Monitoring Context, where titration decisions are informed by measured clinical response.
- Anti-corruption layers translate data from external pharmacy benefit management systems, electronic health records, and FDA reporting platforms into the domain's ubiquitous language.

## Tactical Design

- **Treatment Plan Aggregate** - The root aggregate representing a patient's complete semaglutide treatment course, maintaining the current indication, titration state, and active monitoring schedule.
- **Dose Value Object** - An immutable representation of a semaglutide dose amount with its formulation type (subcutaneous or oral) and frequency, used as the building block for titration schedules.
- **Titration Step Entity** - A planned or completed dose escalation event within the titration schedule, tracking the target dose, actual administration date, and tolerability assessment.
- **Adverse Event Reported Domain Event** - Raised when a clinician documents a side effect, triggering severity-dependent workflows ranging from dose adjustment consideration to mandatory FDA reporting.
- **Eligibility Assessment Value Object** - A composite evaluation capturing BMI, diagnosis codes, contraindication check results, and insurance authorization status as an immutable point-in-time determination.
- **Titration Engine Domain Service** - Calculates the next appropriate dose escalation step based on current dose, elapsed time, tolerability, and clinical response metrics.

## References

- Evans, E. (2003). *Domain-Driven Design: Tackling Complexity in the Heart of Software*. Addison-Wesley.
- Vernon, V. (2013). *Implementing Domain-Driven Design*. Addison-Wesley.
- Khononov, V. (2021). *Learning Domain-Driven Design*. O'Reilly Media.
- Wilding, J. P. H. et al. (2021). *Once-Weekly Semaglutide in Adults with Overweight or Obesity* (STEP 1). New England Journal of Medicine.
- Marso, S. P. et al. (2016). *Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes* (SUSTAIN-6). New England Journal of Medicine.
